Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q4 2014 · 10-K
Revenue$1.67M$1.67M−0.3% vs Q4 2013 Net Income-$10.57M-$10.57MN/M vs Q4 2013 EPS Diluted-$0.14-$0.14N/M vs Q4 2013 Gross Profitderived$1,655,794−0.7% The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
Operating Income-$14,405,000N/M Operating Cash Flowderived-$9,110,192N/M Free Cash Flowderived-$9,096,170N/M Margins · derivedGross margin99.4%−0.4 pt vs Q4 2013
Operating margin-865.2%+888.9 pt vs Q4 2013
Net margin-634.7%+539.6 pt vs Q4 2013
ended Dec 31, 2014 · filed Mar 11, 2015 · 70 d after period end